Updates on the Treatment of Epilepsy in Women

Archives of Internal Medicine

Volumn 164, Issue 2, 2004, Pages 137-145

  Tatum IV, William O ^a,d   Liporace, Joyce ^b   Benbadis, Selim R ^a   Kaplan, Peter W ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; ESTROGEN; ETHINYLESTRADIOL; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GONADORELIN DERIVATIVE; MAGNESIUM SULFATE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PHYTOMENADIONE; PRIMIDONE; PROGESTERONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VITAMIN K GROUP; ZONISAMIDE;

ALOPECIA; ANTICONVULSANT THERAPY; BLEEDING; BODY WEIGHT; BONE DISEASE; CLEFT LIP; CLEFT PALATE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFECT; DRUG INDICATION; ECLAMPSIA AND PREECLAMPSIA; EMBRYOTOXICITY; ENDOCRINE FUNCTION; ENZYME INDUCTION; EPILEPSY; ESTHETICS; ESTROGEN ACTIVITY; FEMALE; FEMALE FERTILITY; FETUS MALFORMATION; FOLIC ACID DEFICIENCY; GABAERGIC TRANSMISSION; GINGIVA HYPERPLASIA; HAIR GROWTH; HIRSUTISM; HORMONAL THERAPY; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INFANT FEEDING; JOINT CONTRACTURE; MENARCHE; MENOPAUSE; NEWBORN HEMORRHAGIC DISEASE; OBESITY; OVARY CYCLE; OVARY POLYCYSTIC DISEASE; PATIENT COUNSELING; PATIENT SELECTION; PREECLAMPSIA; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SEIZURE; SEXUAL FUNCTION; SHORT STATURE; SIDE EFFECT; SYSTEMIC DISEASE; TERATOGENICITY; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; ENDOCRINE SYSTEM; EPILEPSY; FEMALE; HORMONES; HUMANS; MENSTRUAL CYCLE; PREGNANCY; WOMEN'S HEALTH;

EID: 0942287304     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.2.137     Document Type: Review

References (102)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34:453-468.
2. Yerby MS. Special considerations for women with epilepsy. Pharmacotherapy. 2000;20:159S-170S.
3. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology. 1999;53(suppl 1): S42-S48.
4. Abbasi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia. 1999;40:205-210.
5. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology. 1998;51:944-948.
6. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology. 2000;55(suppl 1):S21-S31.
7. Woolley CS, Schwartzkroin PA. Hormonal effects on the brain. Epilepsia. 1998;39(suppl 8): S2-S8.
8. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-d-aspartate receptor-dependent mechanism. J Neurosci. 1994;14:7680-7687.
9. Bauer J. Interactions between hormones and epilepsy in female patients. Epilepsia. 2001;42 (suppl 3):20-22.
10. Stoffel-Wagner V, Bauer J, Flugel D, et al. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia. 1998;39:1164-1173.
11. Sperling MR, Pritchard PB, Engel J, et al. Prolactin in partial epilepsy: an indicator of limbic seizures. Ann Neurol. 1986;20:716-722.
12. Rociszewska D. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49:47-51.
13. Foldvary N. Treatment issues for women with epilepsy. Neurol Clin. 2001;19:409-425.
14. Diamantopoulos N, Crumrine PK. The effect of puberty on the course of epilepsy. Arch Neurol. 1986;43:873-876.
15. Drislane FW, Coleman AE, Schomer KL, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology. 1994;44:306-310.
16. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia. 1988;29:612-619.
17. Benbadis SR, Tatum WO IV. Advances in the treatment of epilepsy. Am Fam Physician. 2001;64:91-106.
18. Duncan S, Read CL, Brodie MJ. How common is catamenial epilepsy? Epilepsia. 1993;34:827-831.
19. Zahn C. Catamenial epilepsy: clinical aspects. Neurology. 1999;53(suppl 1):S34-S37.
20. Liporace JD. Women's issues in epilepsy. Postgrad Med. 1997;102:123-138.
21. Chang S-I, McAuley JW. Pharmacotherapeutic issues for women of childbearing age with epilepsy. Ann Pharmacother. 1998;32:794-801.
22. Herzog AG. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia. 1991;32(suppl 6):S27-S33.
23. Harden CL, Pulver MC, Ravdin L, et al. The effects of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40:1402-1407.
24. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38:1082-1088.
25. Klein P, Herzog AG. Hormonal effects on epilepsy in women. Epilepsia. 1998;39(suppl 8):S9-S16.
26. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1999;52:1917-1918).
27. Bauer J, Wildt L, Flugel D, et al. The effect of a synthetic GnRH analogue on catamenial epilepsy: a study of ten patients. J Neurol. 1992;239:284-286.
28. El-Sayed YY. Obstetric and gynecologic care of women with epilepsy. Epilepsia. 1998;39(suppl 8):S17-S25.
29. Scherer A. The Epilepsy Foundation of American. In: Reisner H, ed. Children With Epilepsy: A Parent's Guide. Washington, DC: Woodbine House Inc; 1988:217-226.
30. Morrell MJ. Effects of epilepsy on women's reproductive health. Epilepsia. 1998;39(suppl 8): S32-S37.
31. Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia. 1996;37:833-840.
32. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women with epilepsy. N Engl J Med. 1993;329:1383-1388.
33. Rattya J, Turkka J, Pakarinen AJ, et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology. 2001;56:31-36.
34. Isojarvi JIT, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43:446-451.
35. Bauer J, Jarre A, Klingmuller D, Elger CE. Polycystic ovary syndrome in patients with focal epilepsy: a study of 93 women. Epilepsy Res. 2000;41:163-167.
36. Morrell MJ. Hormones and epilepsy through the lifetime. Epilepsia. 1992;33(suppl 4):S49-S61.
37. Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. Best practice guidelines for the management of women with epilepsy: the Women With Epilepsy Guidelines Development Group. Seizure. 1999;8:201-217.
38. Harden CL, Pulver MC, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40:1402-1407.
39. Crawford P, Lee P. Gender difference in the management of women: what women are hearing. Seizure. 1999;8:135-139.
40. Morrell MJ. Sexual dysfunction in epilepsy. Epilepsia. 1991;32(suppl 6):S38-S46.
41. Morrell MJ. Maximizing the health of women with epilepsy: science and ethics of new drug development. Epilepsia. 1997;38(suppl 4):S32-S41.
42. Mattson RH, Cramer JA, Darney PD, Naftolin F. The use of oral contraceptives by women with epilepsy. JAMA. 1986;256:238-240.
43. Guberman A. Hormonal contraception and epilepsy. Neurology. 1999;53(suppl 1):S38-S40.
44. Krauss GL, Brandt J, Campbell M, et al. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology. 1996;46:1534-1539.
45. Tatum WO IV, Galvez R, Benbadis SR, Carrazana E. New antiepileptic drugs. Arch Fam Med. 2000;9:1135-1141.
46. Hvas CL, Henriksen TB, Ostergaard JR. Birth weight in offspring of women with epilepsy. Epidemiol Rev. 2000;22:275-282.
47. Hvas CL, McCormick MD. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med. 1985;312:82-90.
48. Murphy DJ, Hope PL, Johnson A. Neonatal risk factors for cerebral palsy in very pre-term babies: case-control study. BMJ. 1997;314:404-408.
49. Nei M, Daly S, Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology. 1998;51:904-906.
50. Morrell MJ. Guidelines for the care of women with epilepsy. Neurology. 1998;51(suppl 4):S21-S27.
51. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia. 1999;40:1231-1236.
52. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344:1132-1138.
53. Leavitt AM, Yerby MS, Robinson N, Sells CJ, Erickson DM. Epilepsy and pregnancy: developmental outcomes at 12 months. Neurology. 1992;42(suppl 5):141-143.
54. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 1991;324:674-677.
55. Zahn C. Neurologic care of pregnant women with epilepsy. Epilepsia. 1998;39(suppl 8):S26-S31.
56. Gaily E, Granstrom M-L. Minor anomalies in children of mothers with epilepsy. Neurology. 1992;42(suppl 5):128-131.
57. Buehler BA, Delimont D, van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med. 1990;322:1567-1572.
58. Lindhout D, Omtzigt JGC. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia. 1994;35(suppl 4):S19-S28.
59. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology. 1992;42(suppl 5):149-160.
60. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology. 1992;42;12-16.
61. MRC Vitamin Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-137.
62. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608-1614.
63. Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res. 1992;13:89-92.
64. Daily LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects: implications for treatment. JAMA. 1995;274:1698-1702.
65. Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: a review of the literature. Neurology. 1998;51:949-956.
66. American Academy of Pediatrics Committee on Nutrition. Vitamin K compounds and their water soluble analogues: use in therapy and prophylaxis in pediatrics. Pediatrics. 1961;25:501-507.
67. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol. 1993;168:923-928.
68. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol. 1993;168:884-888.
69. Yerby MS. Problems and management of the pregnant woman with epilepsy. Epilepsia. 1987;28(suppl 3):S29-S36.
70. Itso S, Moretti M, Liau M, Koren G. Initiation and duration of breast-feeding in women receiving antiepileptics. Am J Obstet Gynecol. 1995;172:881-886.
71. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: open-label, long-term study: Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache. 1999;39:633-643.
72. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia. 1999;40:590-600.
73. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med. 1999;341:427-434.
74. Isojarvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllyla W. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39:579-584.
75. Ahn C, Chung S. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev. 1994;16:382-385.
76. Akin R, Okutan V, Sarici U, et al. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol. 1998;19:129-131.
77. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127:256-262.
78. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57:445-449.
79. Guo Chun-Yuan, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001;42:1141-1147.
80. Rattya J, Vainionpaa L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics. 1999;103:588-593.
81. Morrell MJ. Reproductive and metabolic disorders in women with epilepsy. Epilepsia. 2003;44(suppl 4):11-20.
82. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255-1260.
83. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
84. Duchowny MS, Resnick TJ, Alvarez LA, et al. Epilepsy surgery in the first three years of life. Epilepsia. 1998;39:737-743.
85. Wyllie E. Surgical treatment of epilepsy in children. Pediatr Neurol. 1998;19:179-188.
86. Cascino GD, Sharbrough FW, Hirschorn KA, et al. Surgery for focal epilepsy in the older patient. Neurology. 1991;41:1415-1417.
87. Kaplan PW. The neurologic consequences of eclampsia. Neurologist. 2001;7:357-363.
88. Kaplan PW. Neurologic issues in eclampsia. Rev Neurol. 1999;155:335-341.
89. Sibai BM. Preeclampsia-eclampsia. In: Sciarra JJ, ed. Gynecology and Obstetrics. Vol 2. Philadelphia, Pa: JB Lippincott; 1989:1-12.
90. American College of Obstetric and Gynecology. Management of eclampsia. Tech Bull. 1986;91:1-6.
91. Sheehan HL, Lynch JB. Pathology of Toxaemia of Pregnancy. Baltimore, Md: Williams & Wilkins; 1973.
92. Douglas K, Redman CW. Eclampsia in the United Kingdom. BMJ. 1994;309:1395-1400.
93. Digre KB, Varner MW, Osborn AB, Crawford S. Cranial magnetic resonance imaging in severe preeclampsia vs eclampsia. Arch Neurol. 1993;50:399-406.
94. Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Lancet. 1995;345:1455-1463.
95. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med. 1995;333:201-205.
96. Kaplan PW. Eclampsia. In: Neurologic Disease in Women. New York, NY: Demos Medical Publications; 1998:207-217.
97. Krauss GL, Kaplan PW, Fisher RS. Parenteral magnesium sulfate fails to control electroshock and pentylenetetrazol seizures in mice. Epilepsy Res. 1989;4:201-206.
98. Pritchard JA, Cunningham PG, Pritchard SA. The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases. Am J Obstet Gynecol. 1984;148:951-963.
99. Sibai BM, Spinnato JA, Watson DL, et al. Eclampsia, IV: neurologic findings and future outcome. Am J Obstet Gynecol. 1985;152:184-192.
100. Lamy C, Sharshar T, Mas J-L. Prognosis of cerebrovascular pathology associated with pregnancy and the postpartum period. Rev Neurol (Paris). 1996;152:422-440.
101. Norwitz ER, Repke JT, Kaplan PW. Eclampsia. In: Gilchrist JM, ed. Prognosis in Neurology. Woburn, Mass: Butterworth-Heinemann; 1998:63-67.
102. Morrell MJ, Gidal BE, Montouris G, Zupanc ML. Managing Epilepsy in Women Across the Reproductive Cycle: A CME Monograph for Neurologists. Parsippany, NJ: GlaxoSmithKline; March 2001:1-26.